| Pharmaceutical Information |
| Drug Name |
Idursulfase |
| Drug ID |
BADD_D01132 |
| Description |
Idursulfase is a purified form of human iduronate-2-sulfatase, a lysosomal enzyme. Idursulfase is produced by recombinant DNA technology in a human cell line. Idursulfase is an enzyme that hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from the glycosaminoglycans dermatan sulfate and heparan sulfate in the lysosomes of various cell types. Idursulfase is a 525-amino acid glycoprotein with a molecular weight of approximately 76 kilodaltons. The enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures. The enzyme activity of idursulfase is dependent on the post-translational modification of a specific cysteine to formylglycine. |
| Indications and Usage |
For the treatment of Hunter syndrome in adults and children ages 5 and older. |
| Marketing Status |
approved |
| ATC Code |
A16AB09 |
| DrugBank ID |
DB01271
|
| KEGG ID |
D04499
|
| MeSH ID |
C517982
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D06CZJ
|
| NDC Product Code |
54092-700 |
| UNII |
5W8JGG2651
|
| Synonyms |
idursulfase | Elaprase |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
50936-59-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
